Cara Therapeutics (Germany) Performance
| 69C Stock | EUR 4.84 0.00 0.00% |
Cara Therapeutics holds a performance score of 14 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.82, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cara Therapeutics is expected to be smaller as well. Use Cara Therapeutics total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to analyze future returns on Cara Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cara Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Cara Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 32.1 M | |
| Total Cashflows From Investing Activities | -4.8 M |
Cara |
Cara Therapeutics Relative Risk vs. Return Landscape
If you would invest 252.00 in Cara Therapeutics on December 13, 2024 and sell it today you would earn a total of 232.00 from holding Cara Therapeutics or generate 92.06% return on investment over 90 days. Cara Therapeutics is currently producing 1.5149% returns and takes up 8.0537% volatility of returns over 90 trading days. Put another way, 71% of traded stocks are less volatile than Cara, and 70% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cara Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cara Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cara Therapeutics, and traders can use it to determine the average amount a Cara Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1881
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | 69C | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.05 actual daily | 71 71% of assets are less volatile |
Expected Return
| 1.51 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 14 86% of assets perform better |
Based on monthly moving average Cara Therapeutics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cara Therapeutics by adding it to a well-diversified portfolio.
Cara Therapeutics Fundamentals Growth
Cara Stock prices reflect investors' perceptions of the future prospects and financial health of Cara Therapeutics, and Cara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cara Stock performance.
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.25) % | |||
| Operating Margin | (2.28) % | |||
| Current Valuation | 450.58 M | |||
| Shares Outstanding | 53.73 M | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 14.36 X | |||
| Revenue | 23.03 M | |||
| EBITDA | (88.83 M) | |||
| Cash And Equivalents | 134.45 M | |||
| Cash Per Share | 3.38 X | |||
| Total Debt | 4.99 M | |||
| Debt To Equity | 4.30 % | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | (60.09 M) | |||
| Earnings Per Share | (1.50) X | |||
| Total Asset | 247.06 M | |||
About Cara Therapeutics Performance
By analyzing Cara Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cara Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 55 people.Things to note about Cara Therapeutics performance evaluation
Checking the ongoing alerts about Cara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cara Therapeutics is not yet fully synchronised with the market data | |
| Cara Therapeutics is way too risky over 90 days horizon | |
| Cara Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 23.03 M. Net Loss for the year was (88.44 M) with loss before overhead, payroll, taxes, and interest of (59.67 M). | |
| Cara Therapeutics has accumulated about 134.45 M in cash with (60.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Roughly 66.0% of the company shares are owned by institutions such as pension funds |
- Analyzing Cara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cara Therapeutics' stock. These opinions can provide insight into Cara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutics' price analysis, check to measure Cara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutics is operating at the current time. Most of Cara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutics' price. Additionally, you may evaluate how the addition of Cara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |